Your browser version may not work well with NCBI's Web applications. More information here...
1: Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005984.Click here to read Links

Enteral nutrition for maintenance of remission in Crohn's disease.

Central Manchester and Manchester Children's University Hospitals, Department of Paediatric Gastroenterology, Booth Hall Children's Hospital, Charlestown Road, Blackley, Manchester, UK, M9 7AA. akobeng@aol.com

BACKGROUND: Prevention of relapse is a major issue in the management of Crohn's disease. Corticosteroids and 5-ASA preparations are not effective for the maintenance of remission. Methotrexate, infliximab, 6-mercaptopurine and its prodrug, azathioprine may be effective in maintaining remission, but these drugs may cause significant adverse events. OBJECTIVES: To conduct a systematic review to evaluate the efficacy of enteral nutrition for the maintenance of remission in Crohn's disease. SEARCH STRATEGY: MEDLINE (1966 to January 2007), EMBASE (1984 to January 2007) the Cochrane Central Register of Controlled Trials from the Cochrane Library (Issue 4, 2006) and the IBD/FBD Review Group Specialized Trials Register were searched. The articles cited in each publication were hand searched. SELECTION CRITERIA: Randomised controlled trials which compared enteral nutrition with no intervention, placebo or with any other intervention were eligible for inclusion. DATA COLLECTION AND ANALYSIS: Data extraction and assessment of methodological quality of included studies were independently performed by two authors. The main outcome measure was the occurrence of clinical or endoscopic relapse as defined by the primary studies. Odds ratios and 95% confidence intervals were calculated for dichotomous outcomes. MAIN RESULTS: Two studies were identified that met the inclusion criteria and were included in the review. Statistical pooling of the results of these studies was not possible because the control interventions, and the way outcomes were assessed differed greatly between the two studies. In one study (Takagi 2006), patients who received half of their total daily calorie requirements as elemental diet and the remaining half by normal diet had a significantly lower relapse rate compared to patients who received unrestricted normal diet (9 of 26 versus 16 of 25; OR 0.3, 95% CI 0.09 to 0.94). In the other study (Verma 2001), elemental and polymeric feeds (providing between 35 and 50% of patients' pretrial calorie intake in addition to unrestricted normal food) were equally effective for maintenance of remission and allowing withdrawal of steroid therapy (8 of 19 versus 6 of 14; OR 0.97, 95% CI 0.24 to 3.92). AUTHORS' CONCLUSIONS: The available evidence suggests that supplementary enteral nutritional may be effective for maintenance of remission in Crohn's disease. Whilst larger studies are needed to confirm these findings, enteral nutritional supplementation could be considered as an alternative or as an adjunct to maintenance drug therapy in Crohn's disease.

PMID: 17636816 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Methotrexate (Rheumatrex® , Trexall® )

    Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...

  • Mercaptopurine (Purinethol® )

    Your doctor has ordered the drug mercaptopurine to help treat your illness. The drug is taken by mouth in tablet form.

  • Azathioprine (Azasan® , Imuran® )

    Azathioprine is used with other medications to prevent rejection of kidney transplants. It is also used to treat severe rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain and swellin...

  • » See all 4 drug reports ...